Effect of High Doses of intravenous Vitamin C on Coagulation Factors and Vascular endothelium in Sepsis Patients.

Investigating the effect of high doses of intravenous vitamin C on coagulation factors and vascular endothelium in sepsis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190718044264N1

Enrollment

Registered

2022-12-03

Start date

2020-04-19

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19. Coronavirus infection, unspecified

Interventions

Intervention 1: Control group: They will receive only standard treatment. Intervention 2: Intervention group: In addition to standard treatment (antibiotics, fluid therapy, etc.), they will receive 25

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Having sepsis according to the criteria stated in the surviving sepsis campaign 2016 Guideline based on SOFAScore

Exclusion criteria

Exclusion criteria: Age less than 18 years Age above 80 years pregnancy Suffering from kidney failure: AKI according to the definition of KDIGO guidelines Receiving other antioxidants 24 hours before and during the study (NAC, melatonin and selenium) Receive intravenous fibrinogen Receive intravenous PCC Receiving heparin with a therapeutic dose INR?1.5 (PLT?100000 ) Thrombocytopenia Patients receiving warfarin Hemochromatosis patients Chronic renal failure (GFR?40) More than 48 hours have passed since the onset of sepsis

Design outcomes

Primary

Measure	Time frame
Antithromobin III. Timepoint: From the beginning to the end of the course. Method of measurement: elisa kit.;Neutrophil to lymphocyte ratio. Timepoint: From the beginning to the end of the course. Method of measurement: Counting blood cells (CBC diff).;Syndecan-1. Timepoint: From the beginning to the end of the course. Method of measurement: Kit.;Mortality. Timepoint: From the beginning to the end of the course. Method of measurement: observation.;Vasopressor dose. Timepoint: From the beginning to the end of the course. Method of measurement: observation.;CRP/ALB ratio. Timepoint: From the beginning to the end of the course. Method of measurement: Laboratory.;ACR. Timepoint: From the beginning to the end of the course. Method of measurement: Laboratory.;FDP/D-Dimer Ratio. Timepoint: From the beginning to the end of the course. Method of measurement: Laboratory.	—

Measure

Time frame

Antithromobin III. Timepoint: From the beginning to the end of the course. Method of measurement: elisa kit.;Neutrophil to lymphocyte ratio. Timepoint: From the beginning to the end of the course. Method of measurement: Counting blood cells (CBC diff).;Syndecan-1. Timepoint: From the beginning to the end of the course. Method of measurement: Kit.;Mortality. Timepoint: From the beginning to the end of the course. Method of measurement: observation.;Vasopressor dose. Timepoint: From the beginning to the end of the course. Method of measurement: observation.;CRP/ALB ratio. Timepoint: From the beginning to the end of the course. Method of measurement: Laboratory.;ACR. Timepoint: From the beginning to the end of the course. Method of measurement: Laboratory.;FDP/D-Dimer Ratio. Timepoint: From the beginning to the end of the course. Method of measurement: Laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKiumarth Amini

Tehran University of Medical Sciences

drkiumarthamini1364@gmail.com09808732238602

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026